Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI in cancer care: 7,151 people share their hopes and fears

NCT ID NCT07526441

Knowledge-focused Sponsor: Technical University of Munich Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how cancer patients, the general public, and healthcare professionals use and feel about large language models (like ChatGPT) for making cancer treatment decisions. Over 7,000 people from 30 countries completed a survey. The goal was to understand current usage, concerns about reliability and privacy, and expectations for the future of AI in cancer care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

7,151 people

The number who actually took part.

Started

Mar 2025

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Three cohorts recruited via the Prolific platform: cancer patients with a diagnosis within five years (n=2,316), general population members from the United States and United Kingdom (n=2,000), and licensed healthcare professionals with active patient contact (n=2,835). Stratified sampling applied quotas for age, gender, ethnicity, and education in the general population cohort.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * English language proficiency * Regular internet access * Registered on the Prolific research platform * For cancer patient cohort: self-reported cancer diagnosis within the past five years * For healthcare professional cohort: licensed healthcare practitioner with active patient contact * For general population cohort: resident of the United States or United Kingdom Exclusion Criteria: * Failure on embedded attention check questions (4 checks) * Survey completion time less than 5 minutes or greater than 60 minutes * Straight-line responding pattern detected by consistency validation algorithms * Failure of cohort verification procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artificial intelligence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artificial intelligence Cancer Shared decision making

Contacts and locations

Locations

  • Technical University Munich

    Munich, Bavaria, 81675, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.